

Nocil Ltd.

BSE SENSEX

39,435

S&P CNX 11,844

CMP: INR133 TP: INR172(+29%)

Buy



Nocil Limited

Stock Info

M.Cap. (INR b)	22.0
Avg Turnover, INR m	10
Equity Shares (m)	164
Face Value	10
52-Week Range (INR)	203/ 112
1/6/12 m Rel. Per* (%)	-3/ -31/ -46
*Polative to BSE concer	

*Relative to BSE sensex Data as on 24thMay, 2019

Financials Snapshot (INR bn)

Y/E Mar	2019E	2020E	2021E
Net Sales	10.4	11.2	13.6
Growth (%)	7.8	7.8	20.8
EBITDA	2.9	2.8	3.3
РАТ	1.8	1.8	2.2
EPS (INR)	11.2	10.7	13.1
Gr. (%)	8.8	-4.4	21.6
BV/sh. (INR)	71.1	78.9	88.7
P/E (x)	11.8	12.4	10.2
P/BV (x)	1.9	1.7	1.5
EV/EBITDA (x)	7.3	7.5	6.3
RoE (%)	16.7	14.4	15.7
RoCE (%)	16.7	14.4	15.7

Shareholding pattern (%)

As On	Sept-18	Dec-18	Mar-19					
Promoter	34.1	33.8	33.8					
MFs	5.1	5.1	3.5					
FPIs	4.7	4.2	4.2					
Others	56.1	56.9	58.5					

Investors are advised to refer through disclosures made at the end of the Research Report.

Another weak quarter, given auto industry headwinds

Nocil for Q4FY19 reported weak set of numbers; mainly on the back of weak tyre demand. Revenue/PAT declined by 12%/30% YoY, with OPM contraction of 621bps. The slowdown in the auto sector and the uncertainty surrounding anti-dumping duty could to act as an overhang for the stock in the near term. However, we believe that with new capacities coming on stream, Nocil is well placed to (i) benefit from any auto sales revival and (ii) capture incremental demand from both global/ Indian tyre companies, given its long standing relationship with them. This, along with its debt free balance sheet, consistent free cash flow generation and healthy return ratios, strengthens the growth narrative. We maintain our Buy rating with revised target price of INR172.

Weak volume and OPM contraction pulled down 4Q performance: Both lower volume (-8% YoY) and weak realization led to revenue decline of 12% YoY; first decline in the last 12 quarters. EBITDA also fell by 30% YoY as the margins contracted by 621bps to 24.5% on the back of high inventory losses. Thus PAT also de-grew by 30% YoY, as lower depreciation was offset by lower other income and higher tax outgo. Plant utilization in 4Q was also lower at 82% vs 92% for FY19. However, overall for FY2019, revenue/ PAT grew by 8%/ 9% while margins expanded by 64bps to 28.1%, supported by strong 1H performance.

Upcoming new capacities to support growth: Nocil's capex of INR4.25b is on track and is likely to get fully commissioned by CY19 end, post which the total capacity would double. The increased capacities would benefit Nocil significantly, as and when the auto sales revive. Further it would help Nocil in capturing higher market share, given the upcoming tyre investments both domestically/globally and the shift of raw material procurement by MNCs from China to other countries.

Valuation: We have reduced our FY20/FY21 PAT estimates by 15%/13%; thus expecting Revenue/PAT CAGR of 14%/8% over FY19-21E with OPM contraction of 357bps (assuming ADD gets removed). The stock is trading at 12.4x FY20E and 10.2x FY21E EPS. We maintain BUY rating with a revised target price of INR172/share.

Quarterly Standalone Performance (INR mn)

Q4FY19	Q4FY18	YoY	Q3FY19	QoQ
2,416	2,759	-12.4%	2,612	-7.5%
591	846	-30.2%	725	-18.5%
24.5%	30.7%	-621bps	27.8%	-331bps
358	510	-29.8%	447	-19.9%
14.8	18.5	-366bps	17.1	-228bps
	2,416 591 24.5% 358	2,416 2,759 591 846 24.5% 30.7% 358 510	2,416 2,759 -12.4% 591 846 -30.2% 24.5% 30.7% -621bps 358 510 -29.8%	2,416 2,759 -12.4% 2,612 591 846 -30.2% 725 24.5% 30.7% -621bps 27.8% 358 510 -29.8% 447

Source: Company, MOSL

Sneha Poddar – Research Analyst (sneha.poddar@motilaloswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Concall Highlights

- ✓ Volume guidance: Volume growth fell by 8% in 4QFY19 on the back of weak auto sales and greater supplies from China. For FY19, overall volume growth stood at +3% YoY. Going forward, management has guided for weakness to continue in 1HFY20, while it expects the volume recovery from 2HFY20. Moreover, post capacity commencement, capacity constraint on few of its products would be removed, which would help Nocil in capturing higher volume.
- Rising share of exports: Exports improved by 24% YoY in FY19, taking its share in revenue to ~30% (26% in FY18); which the management is hopeful of expanding further on the back of huge capex lined up by the global tyre companies. It recently started exporting to US and would benefit greatly with the ongoing US-China trade war and the imposition of Anti-Dumping Duty (ADD) by US on China imports. Nocil is confident of increasing its market share internationally as the global companies are strategically shifting their procurement from China to other countries in order to de-risk themselves.
- ✓ ADD removal: Removal of ADD (due for renewal in July'19) by India on Chinese imports would impact EBITDA to the tune of INR400mn (~4% hit on margins) at the present volume level. Currently we have factored that in our estimates. Renewal of the same would be positive for the company.

Y/E March			FY18			FY	'19	
(INR millions)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Net Sales	2,149	2,276	2,493	2,759	2,681	2,720	2,612	2,416
YoY Change (%)	11.5%	25.5%	40.6%	44.6%	24.8%	19.5%	4.8%	-12.4%
QoQ Change (%)	12.6%	5.9%	9.5%	10.7%	-2.8%	1.5%	-4.0%	-7.5%
Total Expenditure	1,602	1,736	1,797	1,913	1,879	1,931	1,887	1,825
EBITDA	547	540	696	846	802	789	725	591
Margins (%)	25.5%	23.7%	27.9%	30.7%	29.9%	29.0%	27.8%	24.5%
Depreciation	36	42	40	112	54	56	56	63
Interest	4	3	3	2	3	1	1	2
Other Income	28	52	32	32	21	32	20	23
РВТ	535	547	685	764	766	764	688	549
Тах	189	167	235	255	258	236	242	191
Rate (%)	35.3%	30.5%	34.3%	33.3%	33.7%	30.8%	35.1%	34.8%
Reported PAT	346	380	450	510	508	528	447	358
Adj PAT	346	380	450	510	508	528	447	358
YoY Change (%)	46.0%	39.7%	81.5%	99.8%	46.8%	39.1%	-0.8%	-29.8%
Margins (%)	16.1%	16.7%	18.1%	18.5%	18.9%	19.4%	17.1%	14.8%

Exhibit 1: Standalone Quarter Earnings


Source: Company, MOSL

Key Risks

- ✓ Any prolonged slowdown in tyre industry than anticipated, which accounts for about two thirds of global rubber consumption can adversely impact demand for rubber chemicals.
- ✓ Although environmental scrutiny in China currently serves as a boon, any relaxation of environmental laws there can lead to increase in global supply impacting realizations.
- ✓ Any delay in new capacity commencement would affect Nocil's volume
- ✓ Sharp movement in crude oil prices could impact prices of key raw materials and hurt margins.


4QFY19 in Charts

Exhibit 4: Q4 revenue slips due to weak volume/realization




Source: Company, MOSL

Exhibit 6: PAT down 30% YoY




Source: Company, MOSL

Exhibit 8: Doubling capacity over FY18-21E





Source: Company, MOSL

Exhibit 5: EBITDA Margins continue its decline




Source: Company, MOSL





Source: Company, MOSL

Exhibit 9: Continues to be debt-free despite capex



Source: Company, MOSL

Company Profile

Company description

Nocil, part of Arvind Mafatlal Group, is India's largest rubber chemicals company offering a range of products such as accelerators (~45% of the portfolio), antidegradants/ antioxidants (~45%), and prevulcanization inhibitors/ post-vulcanization stabilizers (~10%) for over four decades now. It has manufacturing facilities in Navi Mumbai and Dahej.

The company's products are used in both tyre and non-tyre industries. Nocil commands a share of ~45% in the domestic market and 5% in the global market.

Source: Company, MOSL

Exhibit 11: Key shareholding above 1% as on Mar-19

Holder Name	% Holding
Ashish Kacholia	4.3%
Dolly Khanna	2.1%
L&T Emerging Business Fund	1.7%
The New India Assurance Company	1.3%
Principal Dividend Yield Fund	1.2%
	Courses Commenter MOCL

Source: Company, MOSL

Exhibit 12: Top management

Name	Designation
Mr Hrishikesh A. Mafatlal	Promoter & Chairman
Mr S. R. Deo	MD
Mr P. Srinivasan	CFO
Mr R. M. Gadgil	President – Marketing
Dr. Chinmoy Nandi	VP – R&D
	Source: Company, MOSI

Source: Company, MOSL

Exhibit 13: Directors

Name	Name
Hrishikesh A. Mafatlal	C. L. Jain
Rohit Arora	D.N. Mungale
Vilas R. Gupte	P.V. Bhide
N. Sankar	(Ms.) D.N. Raval
S.R. Deo	Priyavrata H. Mafatlal
	Source: Company MOSI

Source: Company, MOSL

Exhibit 14: Auditors

Name	Туре
M/s. Kalyaniwalla & Mistry LLP	Statutory Auditors
M/s. Makarand M. Joshi & Co.	Secretarial Auditor
M/s Kishore Bhatia & Associates	Cost Auditor

Source: Company, MOSL



Nocil Ltd.

Financials and Valuations

Consolidated Income Statement							(INR	Million)
Y/E March	FY14	FY15	FY16	FY17	FY18	FY19	FY20E	FY21E
Net Sales	5,961	7,190	7,152	7,422	9,676	10,429	11,242	13,575
Change (%)	22.1	20.6	-0.5	3.8	30.4	7.8	7.8	20.8
Total Expenditure	5,338	6,057	5,758	5,830	7,022	7,502	8,432	10,249
% of Sales	89.5	84.2	80.5	78.5	72.6	71.9	75.0	75.5
EBITDA	624	1,133	1,394	1,592	2,654	2,927	2,811	3,326
Margin (%)	10.5	15.8	19.5	21.5	27.4	28.1	25.0	24.5
Depreciation	187	145	146	197	240	243	270	282
EBIT	436	988	1,247	1,395	2,414	2,684	2,540	3,044
Int. and Finance Charges	174	165	93	22	12	6	0	C
Other Income	108	40	35	95	146	100	110	180
PBT bef. EO Exp.	371	862	1,189	1,468	2,547	2,777	2,650	3,224
Extraordinary Items	-20	0	0	0	0	0	0	C
РВТ	350	862	1,189	1,468	2,547	2,777	2,650	3,224
Тах	112	291	407	497	848	929	883	1,074
Tax Rate (%)	31.9	33.8	34.2	33.8	33.3	33.4	33.3	33.3
Min. Int. & Assoc. Share	0	0	0	0	0	0	0	C
Reported PAT	239	571	783	971	1,699	1,849	1,768	2,150
Adjusted PAT	252	571	783	971	1,699	1,849	1,768	2,150
Change (%)	21.7	126.2	37.1	24.1	75.0	8.8	-4.4	21.6
Margin (%)	4.2	7.9	10.9	13.1	17.6	17.7	15.7	15.8
Consolidated Balance Sheet							(IN	R Million)
Y/E March	FY14	FY15	FY16	FY17	FY18	FY19	FY20E	FY21E
Share Capital	1,608	1,608	1,608	1,636	1,645	1,654	1,654	1,654
Reserves	2,168	2,542	6,084	7,496	8,822	9,976	11,247	12,852
Net Worth	3,776	4,150	7,692	9,131	10,467	11,630	12,902	14,506
Debt	1,522	1,473	259	150	50	0	0	C
Deferred Tax (Net)	403	429	1,039	1,063	1,041	1,094	1,094	1,095
Total Capital Employed	5,700	6,052	8,990	10,345	11,558	12,724	13,995	15,600
Gross Fixed Assets	4,484	4,507	7,009	7,084	7,022	8,558	9,088	9,338
Less: Accumulated Depreciation	1,280	1,398	1,519	1,658	1,744	1,987	2,258	2,540
Net Fixed Assets	3,204	3,109	5,489	5,426	5,277	6,570	6,830	6,798

Total Capital Employed	5,700	6,052	8,990	10,345	11,558	12,724	13,995	15,600
Gross Fixed Assets	4,484	4,507	7,009	7,084	7,022	8,558	9,088	9,338
Less: Accumulated Depreciation	1,280	1,398	1,519	1,658	1,744	1,987	2,258	2,540
Net Fixed Assets	3,204	3,109	5,489	5,426	5,277	6,570	6,830	6,798
Capital WIP	29	34	61	45	425	1,313	50	50
Investments	224	224	1,120	1,764	2,812	1,272	3,272	4,272
Current Assets	3,866	4,184	3,467	4,376	4,797	5,267	5,692	6,742
Inventory	1,601	1,877	1,326	1,146	1,553	1,707	1,879	2,194
Debtors	1,477	1,672	1,508	1,665	2,434	2,322	2,618	2,975
Cash and Bank Balance	153	75	157	1,222	320	424	641	828
Loans and Advances & OCA	635	559	476	342	490	814	554	744
Current Liability & Provisions	1,623	1,499	1,148	1,265	1,754	1,699	1,849	2,262
Account Payables	1,173	839	693	812	1,157	983	1,294	1,488
Current Liabilities	196	304	251	242	362	499	339	558
Oth. Long Term Liab. & Prov.	255	357	203	211	235	217	217	217
Net Current Assets	2,243	2,685	2,320	3,111	3,044	3,568	3,843	4,479
Appl. of Funds	5,700	6,052	8,990	10,345	11,558	12,724	13,995	15,600

Ratios Y/E March Basic (INR)

 FY14	FY15	FY16	FY17	FY18	FY19	FY20E	FY21E
1.5	3.5	4.8	5.9	10.3	11.2	10.7	13.1
2.7	4.4	5.7	7.1	11.9	12.8	12.5	14.9
23.1	25.4	47.0	55.8	64.0	71.1	78.9	88.7
0.6	1.0	1.2	1.8	2.5	2.5	2.5	2.8
47.3	33.9	29.7	36.2	29.0	26.8	28.1	25.4

Basie (intri)								
EPS	1.5	3.5	4.8	5.9	10.3	11.2	10.7	13.1
Cash EPS	2.7	4.4	5.7	7.1	11.9	12.8	12.5	14.9
BV/Share	23.1	25.4	47.0	55.8	64.0	71.1	78.9	88.7
DPS	0.6	1.0	1.2	1.8	2.5	2.5	2.5	2.8
Payout (%)	47.3	33.9	29.7	36.2	29.0	26.8	28.1	25.4
Valuation (x)								
P/E	86.2	38.1	27.8	22.4	12.9	11.8	12.4	10.2
Cash P/E	49.5	30.4	23.4	18.6	11.2	10.4	10.7	8.9
P/BV	5.8	5.2	2.8	2.4	2.1	1.9	1.7	1.5
EV/Sales	3.9	3.2	3.1	2.8	2.2	2.0	1.9	1.5
EV/EBITDA	37.1	20.4	15.7	13.0	8.1	7.3	7.5	6.3
Dividend Yield (%)	0.4	0.7	0.9	1.4	1.9	1.9	1.9	2.1
FCF per share	1.0	1.3	9.2	7.9	3.1	-5.2	15.9	9.5
Return Ratios (%)								
RoE	6.8	14.4	13.2	11.5	17.3	16.7	14.4	15.7
RoCE	7.1	12.5	12.4	11.4	17.2	16.7	14.4	15.7
Working Capital Ratios								
Asset Turnover (x)	1.0	1.2	0.8	0.7	0.8	0.8	0.8	0.9
Inventory (Days)	98	95	68	56	59	60	61	59
Debtor (Days)	90	85	77	82	92	81	85	80
Creditor (Days)	72	43	35	40	44	34	42	40
Leverage Ratio (x)								
Net Debt/Equity	0.3	0.3	-0.1	-0.3	-0.3	-0.1	-0.3	-0.4

Consolidated Cash Flow Statement (INR Million)							R Million)	
Y/E March	FY14	FY15	FY16	FY17	FY18	FY19E	FY20E	FY21E
OP/(Loss) before Tax	350	862	1,181	1,468	2,547	2,777	2,650	3,224
Depreciation	187	145	137	197	240	243	270	282
Interest & Finance Charges	174	165	93	22	12	6	0	0
Direct Taxes Paid	-36	-188	-306	-455	-806	-929	-883	-1,074
(Inc.)/Dec in WC	-136	-659	576	278	-876	-421	-58	-449
CF from Operations	540	325	1,682	1,511	1,118	1,677	1,980	1,983
Others	-98	-24	-31	-89	-90	-100	-110	-180
CF from Operating incl. EO	442	300	1,651	1,422	1,028	1,578	1,870	1,803
(Inc.)/Dec in FA	-280	-88	-140	-129	-516	-2,424	733	-250
Free Cash Flow	162	212	1,511	1,293	512	-846	2,602	1,553
(Pur.)/Sale of Investments	0	0	0	-47	-943	1,562	-2,000	-1,000
Others	102	35	16	81	35	100	110	180
CF from Investments	-178	-53	-124	-96	-1,423	-762	-1,157	-1,070
Issue of Shares	0	0	0	57	41	-136	0	0
Inc./(Dec) in Debt	54	-49	-1,214	-109	-100	-50	0	0
Interest Paid	-174	-165	-101	-23	-13	-6	0	0
Dividend Paid	-112	-112	-192	-231	-351	-496	-496	-546
CF from Fin. Activity	-232	-326	-1,508	-306	-422	-689	-496	-546
Inc./Dec of Cash	32	-79	20	1,020	-817	127	216	187
Unrealized Forex fluctuation	-1	0	3	-9	2	0	0	0
Opening Balance	109	140	26	49	1,060	244	371	587
Other Bank Balance	13	14	109	163	77	54	54	54
Closing Balance	153	75	157	1,222	321	425	641	828

6

This report is intended for distribution to Retail Investors

Explanation of Investment Rating			
Investment Rating	xpected return (over 12-month)		
BUY	>=15%		
SELL	< - 10%		
NEUTRAL	< - 10 % to 15%		
UNDER REVIEW	Rating may undergo a change		
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation		

Disclosures

Disclosures The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations). Motial Oswal Securities Ltd. (MOSL)* is a SEBI Registered Research Analyst having registration no. INH000000412. MOSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOSL is a subsidiary company of Motial Oswal Financial Service Ltd. (MOFSL). MOFSL is a listed public company, the details in respect of which are available on www.motialoswal.com, MOSL is registered vith the Securities & Exchange Board of India (SEBI) and is a registered vithing Member with National Stock Exchange of India Ltd. (MSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India (MCX) & National Commodity & Derivatives Exchange Ltd. (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) & National Securities Depository Limited (NSDL) and is member of Association of Mutual Funds of India (SeuCOSC) and is member of Association of Mutual Funds of India (MAFF) for distribution of financial products. Details of associate entities of Motial Oswal Securities Limited are available on the website at http://onineepost.motialeswal.com/Dommat/Gourment/List%200FW20Associate%20Commanies.odf

http://onlinereports.moltialoswal.com/Dormant/documents/List%2007%/200

by the latarysts), is the recommendations made by the analysts is not comparison in accepted in its research reports. As a result, the recipients of this report should be aware that MOSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Securities Limited are available on the website at <u>https://galaxy.motilaloswal.com/ResearchAnalystPublishViewLitigation.aspx</u> A graph of daily closing prices of securities is available at <u>www.nseindia.com</u>, <u>www.bseindia.com</u>, <u>Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have</u>

Regional Disclosures (outside India) This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSL & its group companies to registration or licensing requirements within such jurisdictions.

MOSL & its group companies to registration or incensing requirements within such private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "FO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors". Nothing here is an offer or solicitation of these securities, and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is drawn to located in Hong Kong & are not conducting Research Analysis in Hong Kong. For U.S.

qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducung Research analysts in Hong Kong. For U.S. Motifal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Actis), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by the U.S. Recurities and Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Contact business with Institutional Investors based in the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered / qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by

Subject to MASD the 2711 and MASD the 2711 and MASD Role 472 restrictions on communication with a subject company, public appearances and reduing sectimes need by a research analyst account. For Singapore In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 2011294012) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact. MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL. Specific Directoreure

Specific Disclosures

ecific Disclosures MOSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company. MOSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company MOSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months MOSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company in the past 12 months MOSL, Research Analyst has not served as director/officer/employee in the subject company in the subject company at the time of publication of research report Research Analyst has not served as director/officer/employee is securities of the subject company in past 12 months MOSL has not received compensation for investment banking/merchant banking/brokerage services from the subject company in the past 12 months MOSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months MOSL has not received compensation or other benefits from third party in connection with the research report MOSL has not received any compensation or other benefits from third party in connection with the research report MOSL has not received any compensation or other benefits from third party in connection with the research report

10

The associates of MOSL may have:

The associates of whoch may have. Infrancial interest in the subject company actual/beneficial ownership of 1% or more securities in the subject company received compensation/other benefits from the subject company in the past 12 months other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report. acted as a manager or commanger of public offering of securities of the subject company in past 12 months be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

company(ies)

companylies) received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services. The associates of MOSL has not received any compensation or other benefits from third party in connection with the research report. Above disclosures include beneficial holdings lying in demat account of MOSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOSL for other purposes (i.e holding client securities, collaterals, collaterals, collaterals, collaterals, collaterals, error trade set (i.e.). MOSL also earns DP income from clients which are not ensidered in above disclosures. Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. Terms & Conditions:

Terms & Conditions: This report has been prepared by MOSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOSL will not treat recipients as customers by virtue of their receiving this report. Disclaimer:

The proof is as customers by virtue of their receiving this report. Disclaimer: The report and information contained herein is stictly confidential and mean solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without updown to your specific circumstances. This report constitutes investment here in is salely for the selected recipient and may not be altered as an offer document or solicitation of offer to by or sell or subscription of the excissed of independent judgenent by any recipient. Each recipient of this focument should make such investigations as it deems necessary to anive a lan independent evaluation of an investment and to part on a whole, to any othe subscription of the excissed of independent judgenent by any recipient. Each recipient of this document to alter devaluation of an investment discussed or views expressed in any evaluation can any event evaluation of an investment and rest and risks of such an investment and risks involved), and should consult its own advisors to determine the metis and risks of such an investment in part of all investors. The securities of all investors the any event evaluation of an investment and risks of such an investment in part of the views expressed in the investment in the observes the right to make and thermations is balable to change without any prior notice. The Gompany reserves the right to make modifications and alternations is subject to change without any prior approval. MOSL, its associates, their differences and rest or part and rest of subscription or parts (or market or approval), and the device or any other subscription and rest of a sub an investment incord without constant and the part and rest of a sub and rest of approval and risks involved, and the comand and the relation and the parts and risks involved, and